SCHEMBL2471550

SCHEMBL2471550

COc1cccc(C2(C(Cc3ccccc3)NC(=O)c3ccccc3OC)CCNCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 2/20 0.42
CHRM3 P20309 1/20 0.42
CCR8 P51685 2/20 0.41
KCNH2 Q12809 1/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 1/20 0.41
GLA P06280 1/20 0.41
KCNA3 P22001 4/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ITGA4 P13612 1/20 0.40
ITGB7 P26010 1/20 0.40
LMNA P02545 1/20 0.40
CAPN1 P07384 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2465742 0.90 PSMB5 (0.43) MEN1KMT2AALDH1A1CHRM3HPGD
SCHEMBL2470270 0.88 ALDH1A1 (0.47) MEN1KMT2AALDH1A1CHRM3HPGD
SCHEMBL2470590 0.83 PSMB5 (0.52) MEN1KMT2AALDH1A1HPGDKCNA3
SCHEMBL2470620 0.81 SMN1; SMN2 (0.43) MEN1KMT2AALDH1A1CHRM3HPGD
SCHEMBL2472644 0.81 ALDH1A1 (0.39) MEN1KMT2AALDH1A1CCR8HPGD
SCHEMBL2468205 0.80 ITGA4 (0.42) MEN1KMT2AALDH1A1CCR8KCNH2
SCHEMBL2469393 0.79 ITGA4 (0.38) ALDH1A1CCR8KCNH2ITGA4ITGB7
SCHEMBL5571593 0.76 FPR2 (0.43) KMT2AALDH1A1CHRM3SMN1; SMN2ITGA4
SCHEMBL2470024 0.76 MEN1 (0.64) MEN1KMT2AALDH1A1KCNA3
SCHEMBL2472052 0.75 CTRB1 (0.46) HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 MEN1 3501/4885KMT2A 957/4885ALDH1A1 3941/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 MEN1 3501/4885KMT2A 957/4885ALDH1A1 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.